CN101638435B - 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用 - Google Patents

一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用 Download PDF

Info

Publication number
CN101638435B
CN101638435B CN2009101920630A CN200910192063A CN101638435B CN 101638435 B CN101638435 B CN 101638435B CN 2009101920630 A CN2009101920630 A CN 2009101920630A CN 200910192063 A CN200910192063 A CN 200910192063A CN 101638435 B CN101638435 B CN 101638435B
Authority
CN
China
Prior art keywords
lcvn
mutant
sequence
protein
cvn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009101920630A
Other languages
English (en)
Chinese (zh)
Other versions
CN101638435A (zh
Inventor
熊盛
陈伟
钱垂文
王一飞
北里海雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan University
Original Assignee
Jinan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan University filed Critical Jinan University
Priority to CN2009101920630A priority Critical patent/CN101638435B/zh
Publication of CN101638435A publication Critical patent/CN101638435A/zh
Priority to JP2012527184A priority patent/JP5592490B2/ja
Priority to IN2837DEN2012 priority patent/IN2012DN02837A/en
Priority to PCT/CN2010/073124 priority patent/WO2011026351A1/zh
Application granted granted Critical
Publication of CN101638435B publication Critical patent/CN101638435B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN2009101920630A 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用 Expired - Fee Related CN101638435B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2009101920630A CN101638435B (zh) 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
JP2012527184A JP5592490B2 (ja) 2009-09-04 2010-05-24 シアノビリン−ｎ変異体、その修飾誘導体及びその応用
IN2837DEN2012 IN2012DN02837A (enExample) 2009-09-04 2010-05-24
PCT/CN2010/073124 WO2011026351A1 (zh) 2009-09-04 2010-05-24 一种蓝藻病毒蛋白n 突变体、其修饰衍生物及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2009101920630A CN101638435B (zh) 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Publications (2)

Publication Number Publication Date
CN101638435A CN101638435A (zh) 2010-02-03
CN101638435B true CN101638435B (zh) 2011-11-16

Family

ID=41613629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009101920630A Expired - Fee Related CN101638435B (zh) 2009-09-04 2009-09-04 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Country Status (4)

Country Link
JP (1) JP5592490B2 (enExample)
CN (1) CN101638435B (enExample)
IN (1) IN2012DN02837A (enExample)
WO (1) WO2011026351A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
EP2955192B1 (en) * 2013-02-05 2020-07-01 Agricultural Technology Research Institute Anti-mycoplasma spp. subunit vaccine
CN110903363A (zh) * 2019-11-26 2020-03-24 中国药科大学 一种蓝藻抗病毒蛋白n的制备方法及应用
CN111494604B (zh) * 2020-05-11 2022-05-06 中国药科大学 蓝藻抗病毒蛋白n在制备抗炎药物中的应用
US20230355708A1 (en) * 2020-09-29 2023-11-09 Drexel University Compositions for inhibiting viral entry and methods using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843882A (en) * 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
WO2003080115A1 (fr) * 2002-03-22 2003-10-02 Bipha Corporation Complexes peptide hydrophile - immunoglobuline
WO2004056852A2 (en) * 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
CN101705241B (zh) * 2008-09-28 2012-06-06 暨南大学 重组蓝藻抗病毒蛋白的制备方法及应用
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Gao X.L. et al.Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion.《Applied Microbiology and Biotechnology》.2009,第85卷(第4期), *
吕锐 等.蓝藻抗病毒蛋白N基因的原核表达及重组蛋白的纯化和复性.《医学研究生学报》.2007,第20卷(第11期), *
庞峰等.蓝藻抗病毒蛋白N的研究进展.《中国海洋药物杂志》.2006,第25卷(第6期), *
黄小花等.蓝藻抗病毒蛋白-N在大肠杆菌中的表达及其抗体的制备.《中国免疫学杂志》.2007,第23卷(第12期), *

Also Published As

Publication number Publication date
CN101638435A (zh) 2010-02-03
WO2011026351A1 (zh) 2011-03-10
IN2012DN02837A (enExample) 2015-07-24
JP2013503609A (ja) 2013-02-04
JP5592490B2 (ja) 2014-09-17

Similar Documents

Publication Publication Date Title
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
EP2007804B1 (en) Glp-1 compounds
JP4903891B2 (ja) シアノビリン変異体−ポリマー接合体
CN102532301B (zh) 一类新型的Exendin-4类似物及其制备方法
CN101638435B (zh) 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用
CN110023333B (zh) 高亲和力的可溶性pd-1分子
WO1992004374A1 (fr) Nouveau polypeptide et medicament anti-vih prepare a partir de ce polypeptide
CN1488641A (zh) 抑制sars冠状病毒的多肽药物及其衍生物和其应用
US20080171060A1 (en) Modulation of immune response and methods based thereon
CN101747437B (zh) 凋亡素-ec-sod羧基末端蛋白转导域融合蛋白
WO2026021236A1 (zh) 可抑制类mers冠状病毒感染的多肽及其应用
CA2348308A1 (en) Rantes-derived peptides with anti-hiv activity
KR20070118492A (ko) N-말단이 수식된 peg-trail 결합체, 이의 제조방법 및 이의 용도
CN109400711B (zh) 一种PDGFRβ靶向性肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
CN100390200C (zh) 一种用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
CN110551179B (zh) 一种经修饰的抗hiv多肽及其制备方法和用途
CN115028742A (zh) 一种鸭α干扰素与鸭白介素2融合蛋白及其编码基因和应用
CN1752211B (zh) 用于治疗获得性免疫缺陷综合征的重组靶向融合蛋白
CN110386985A (zh) 一种肿瘤靶向性促凋亡融合蛋白及其用途
CN101104856B (zh) 一个系列的非病毒载体及包含其的药物组合物
HK40118032A (zh) 可抑制类mers冠状病毒感染的多肽及其应用
CN104177501A (zh) 蝎镇痛抗肿瘤缬精甘肽融合体及其获得方法
CN113845599A (zh) 一种重组猪干扰素融合蛋白及其应用
CN103214584A (zh) 具有抑制肿瘤微环境血管再生和激活适应性免疫应答双功能的融合蛋白及其基因和应用
KR20090118626A (ko) 알지디-폴리에틸렌 글리콜이 수식된 트레일, 이의제조방법, 및 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111116

Termination date: 20210904